
|Videos|May 9, 2014
Dutasteride for the Treatment of Prostate Cancer
Author(s)Rana R. McKay, MD
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.
Advertisement
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.
- Dutasteride is a dual 5-α reductase inhibitor that prevents the conversion of testosterone to DHT. It is classically used for people with benign prostatic hypertrophy.
- In a phase II trial, dutasteride was combined with abiraterone acetate for the treatment of metastatic castration resistant prostate cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
New OrigAMI-1 Data Signal Shift Beyond First-Gen EGFR Inhibitors in Metastatic CRC
2
Epcoritamab Monotherapy Yields Positive Results in Phase 3 R/R DLBCL Trial
3
EMA Validates T-DXd for First-Line HER2+ Metastatic Breast Cancer
4
Breakthroughs in Oncology: Validating Real Gains in Cancer Survival
5













































